Hansoh Pharma's HS-20089 receives breakthrough therapy designation in China

Hansoh Pharmaceutical Group Company Limited (HKEX:3692) announced today that its self-developed B7-H4-targeted antibody-drug conjugate (ADC), HS-20089, has been granted Breakthrough Therapy designation by the NMPA in China. The designation supports HS-20089's development as a potential treatment for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients. HS-20089 is currently undergoing Phase III clinical trials in China. Notably, in October 2023, Hansoh entered an exclusive licensing agreement with GlaxoSmithKline (GSK), granting GSK exclusive worldwide rights (excluding Mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize the product. Phase I clinical trials overseas by GSK are ongoing.